We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ABACAVIR/LAMIVUDINE SUN (Sun Pharma ANZ Pty Ltd)
Product name
ABACAVIR/LAMIVUDINE SUN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
164 working days (255)
Active ingredients
Abacavir sulfate; Lamivudine
Registration type
New generic medicine
Indication
ABACAVIR/LAMIVUDINE (tablets) is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.